Rocket Doctor AI (TSE:AIDR)
:AIDR
Top Page
Rocket Doctor AI
(AIDR)
Select Model
Select Model
Rating:48Neutral
Price Target:
C$0.76
â–²(27.00% Upside)
Action:UpgradedDate:12/30/25
The score is primarily held down by weak financial performance—minimal revenue scale, large operating losses, and sharply worsening cash burn—implying high execution and funding risk. Technicals are also soft (negative MACD and price below short/intermediate moving averages). Offsetting factors include a string of positive corporate developments (U.S. insurer access expansion, funding/grants, partnerships, and an announced acquisition), but valuation support is limited given negative earnings and no dividend yield provided.
Positive Factors
Low Leverage
Low debt-to-equity (~0.19) provides durable financial flexibility, reducing interest burden and preserving borrowing capacity. This structural advantage helps the company withstand execution risk while pursuing product rollouts or M&A without immediate refinancing pressure.
Negative Factors
Severe Cash Burn
Accelerating cash burn (-$4.44M in 2024 vs -$0.74M in 2023) creates a structural funding risk over the medium term. Persistent outflows force management to secure capital, potentially diluting shareholders and diverting focus from long-term product and market development.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Low debt-to-equity (~0.19) provides durable financial flexibility, reducing interest burden and preserving borrowing capacity. This structural advantage helps the company withstand execution risk while pursuing product rollouts or M&A without immediate refinancing pressure.
Read all positive factors
Rocket Doctor AI (AIDR) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$50.98M
Dividend YieldN/A
Average Volume (3M)175.17K
Price to Earnings (P/E)―
Beta (1Y)0.43
Revenue GrowthN/A
EPS Growth7.04%
CountryCA
Employees3
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.05
Shares Outstanding84,969,680
10 Day Avg. Volume215,584
30 Day Avg. Volume175,170
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)30.15
Price to Sales (P/S)2175.03
P/FCF Ratio-5.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$2.10Price Target Upside249.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Rocket Doctor AI Business Overview & Revenue Model
Company Description
Rocket Doctor AI Inc. provides personalized health care information services in Canada. The company develops a mobile application for symptom assessment of users to address their health concerns, problems, and ongoing wellness management. It also ...
How the Company Makes Money
Treatment.com International (TRUE) generates revenue primarily through licensing and subscription fees for its digital health platforms and solutions. The company's key revenue streams include partnerships with healthcare providers, insurance comp...
Rocket Doctor AI Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
34
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 523.75K | 10.99K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 468.15K | 10.99K | 0.00 | -377.28K | -656.40K | -326.85K |
| EBITDA | -8.73M | -7.52M | -2.33M | 0.00 | 0.00 | 0.00 |
| Net Income | -8.75M | -7.55M | -3.72M | -3.80M | -13.86M | -2.91M |
Balance Sheet | ||||||
| Total Assets | 18.54M | 1.28M | 739.31K | 13.67K | 942.51K | 313.20K |
| Cash, Cash Equivalents and Short-Term Investments | 117.59K | 1.23M | 715.53K | 2.50K | 916.75K | 312.64K |
| Total Debt | 613.46K | 152.00K | 584.79K | 566.28K | 0.00 | 0.00 |
| Total Liabilities | 10.45M | 486.43K | 1.48M | 2.20M | 832.62K | 576.46K |
| Stockholders Equity | 8.09M | 792.77K | -738.05K | -2.19M | 109.90K | -263.26K |
Cash Flow | ||||||
| Free Cash Flow | -5.08M | -4.44M | -740.08K | -1.46M | -6.29M | -2.01M |
| Operating Cash Flow | -5.08M | -4.44M | -740.08K | -1.46M | -6.29M | -2.01M |
| Investing Cash Flow | -1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 5.60M | 4.97M | 1.45M | 540.62K | 6.94M | 1.86M |
Rocket Doctor AI Technical Analysis
Negative
0.60
Price Trends
0.67
Negative
0.73
Negative
0.67
Negative
Market Momentum
-0.02
Negative
47.12
Neutral
62.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AIDR, the sentiment is Negative. The current price of 0.6 is below the 20-day moving average (MA) of 0.61, below the 50-day MA of 0.67, and below the 200-day MA of 0.67, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.12 is Neutral, neither overbought nor oversold. The STOCH value of 62.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AIDR.
Rocket Doctor AI Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | C$436.30M | 90.72 | 2.75% | ― | 59.34% | -23.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$50.98M | -2.31 | -207.53% | ― | ― | 7.04% | |
45 Neutral | C$33.11M | -9.48 | 3086.87% | ― | -48.53% | -9.66% | |
45 Neutral | C$2.69M | -4.56 | -34.06% | ― | -100.00% | 65.85% | |
42 Neutral | C$9.93M | -5.12 | 6239.15% | ― | ― | 48.94% | |
| ― | C$10.28M | -21.40 | 527.45% | ― | ― | -67.11% |
* Healthcare Sector Average
TSE:AIDR
Rocket Doctor AI
0.60
0.18
42.86%
TSE:ADK
Diagnos
0.28
<0.01
1.85%
TSE:VHI
Vitalhub
6.90
-2.80
-28.87%
TSE:NDAT
nDatalyze Corp
0.07
0.04
160.00%
TSE:UDOC
UniDoc Health Corp
0.12
-0.20
-62.90%
TSE:DMED
DiagnaMed Holdings Corp.
0.09
0.07
260.00%
Rocket Doctor AI Corporate Events
Business Operations and Strategy
Rocket Doctor AI Expands U.S. Footprint With New California Insurer Deal
Positive
Jan 27, 2026
Rocket Doctor AI has signed a new in-network agreement with a major commercial insurer in California, extending digital access to its network of board-certified physicians to approximately 175,000 additional members and lifting its total in-networ...
Business Operations and StrategyPrivate Placements and Financing
Rocket Doctor AI Raises C$5.2 Million to Fuel AI-Driven Digital Health Expansion
Positive
Jan 22, 2026
Rocket Doctor AI Inc. has closed a non-brokered private placement of 7,428,571 units at C$0.70 per unit, raising approximately C$5.2 million, with each unit comprising one common share and one warrant exercisable at C$0.85 until January 22, 2027. ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Rocket Doctor AI Upsizes LIFE Private Placement to $5.2 Million Amid Strong Demand
Positive
Jan 20, 2026
Rocket Doctor AI Inc., a physician-led medical AI and digital health platform provider, has increased the size of its previously announced non-brokered private placement under the listed issuer financing exemption to a maximum of $5.2 million in g...
Business Operations and StrategyPrivate Placements and Financing
Rocket Doctor AI Upsizes Private Placement to $4.5 Million on Strong Demand
Positive
Jan 19, 2026
Rocket Doctor AI Inc. has increased the size of its previously announced non-brokered private placement under the listed issuer financing exemption to a maximum of $4.5 million in gross proceeds, with units priced at $0.70 each, citing strong inve...
Business Operations and Strategy
Rocket Doctor AI Grants Stock Options and RSUs to Support Growth in AI-Driven Healthcare
Positive
Jan 13, 2026
Rocket Doctor AI Inc. has granted a total of 75,000 stock options, exercisable at $0.74 per share for three years, and 212,148 restricted share units, also with a three-year term, to its consultants under existing share compensation plans, with al...
Business Operations and StrategyM&A Transactions
Rocket Doctor AI Closes Alea Health Acquisition to Bolster Digital Mental Health Platform
Positive
Jan 13, 2026
Rocket Doctor AI has completed the acquisition of Alea Health Holdings, adding therapist-led mental health capabilities and complementary clinical workflow and decision-support technology to its AI-driven digital health platform. The all-share-and...
Business Operations and StrategyPrivate Placements and Financing
Rocket Doctor AI Seeks $3 Million in Non-Brokered LIFE Financing to Fuel AI Health Platform Growth
Positive
Jan 9, 2026
Rocket Doctor AI Inc. has launched a non-brokered private placement under Canada’s listed issuer financing exemption to raise a minimum of approximately $3 million through the sale of 4,285,715 units at $0.70 each, with each unit comprising ...
Business Operations and StrategyProduct-Related Announcements
Rocket Doctor AI Partners to Launch AI-Powered Clinical Support in Alberta
Positive
Dec 8, 2025
Rocket Doctor AI has partnered with the CAN Health Network and Health Cities to launch an AI-powered Clinical Decision Support System (CDSS) in Alberta. The initiative, set to begin in December 2025, will initially be implemented at four primary c...
Business Operations and StrategyExecutive/Board Changes
Rocket Doctor AI Announces Leadership Change and Stock Option Grants
Neutral
Dec 5, 2025
Rocket Doctor AI Inc. has announced a change in its executive team, with Christopher Cherry stepping in as the Interim Chief Financial Officer, replacing David Worner. The company has also granted stock options and restricted share units to its ex...
Business Operations and Strategy
Rocket Doctor Partners with TMU to Enhance Medical Education in Canada
Positive
Dec 4, 2025
Rocket Doctor AI Inc., through its digital health platform Rocket Doctor, has announced a strategic partnership with Toronto Metropolitan University (TMU) to enhance clinical education for medical learners in Canada. This collaboration aims to exp...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Rocket Doctor AI Gains Momentum with U.S. Expansion and Strategic Initiatives
Positive
Dec 2, 2025
Rocket Doctor AI reported strong momentum in Q3 2025, driven by its U.S. expansion, new payer contracts, and platform growth. The company achieved continued revenue growth despite seasonal challenges and improved its cash position with a successfu...
Business Operations and StrategyM&A Transactions
Rocket Doctor AI Acquires Alea Health to Boost AI-Driven Mental Health Solutions
Positive
Nov 19, 2025
Rocket Doctor AI has entered into a definitive agreement to acquire Alea Health Holdings Ltd., aiming to enhance its capabilities in AI-driven mental health solutions. The acquisition will integrate Alea’s advanced online therapy platform wi...
Business Operations and StrategyExecutive/Board Changes
Rocket Doctor AI Expands U.S. Leadership to Boost Growth and Healthcare Access
Positive
Nov 5, 2025
Rocket Doctor AI Inc. has announced the appointment of four senior leaders to its U.S. operations as part of a strategic initiative to accelerate growth and expand its digital health platform across key states. This move aims to strengthen the com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.